Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.05 is 46% above its 5-year average of -1.95, near the high end of its 5-year range (-2.91–-1.05).
24.73% above its 12-month average of -1.40.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.25.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.05
EARNINGS PER SHARE (EPS) AVG TTM
-1.40
EARNINGS PER SHARE (EPS) AVG 3Y
-1.83
EARNINGS PER SHARE (EPS) AVG 5Y
-1.95
EARNINGS PER SHARE (EPS) AVG 10Y
-1.60
EARNINGS PER SHARE (EPS) AVG 15Y
-1.44
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+24.73%
CURRENT VS 3Y AVG
+42.78%
CURRENT VS 5Y AVG
+46.06%
CURRENT VS 10Y AVG
+34.19%
CURRENT VS 15Y AVG
+26.87%
CURRENT VS 20Y AVG
N/A
Fate Therapeutics, Inc.
Market Cap
$275.66M
Earnings Per Share (EPS)
-1.05
TTM Avg
-1.40
3Y Avg
-1.83
5Y Avg
-1.95
Market Cap
$274.22M
Earnings Per Share (EPS)
-0.17
TTM Avg
-2.37
3Y Avg
-2.73
5Y Avg
-2.69
Market Cap
$272.42M
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$277.96M
Earnings Per Share (EPS)
-0.86
TTM Avg
-1.73
3Y Avg
-3.85
5Y Avg
-2.38
Market Cap
$279.29M
Earnings Per Share (EPS)
-1.39
TTM Avg
-0.76
3Y Avg
-0.82
5Y Avg
-19.50
Market Cap
$282.68M
Earnings Per Share (EPS)
-1.21
TTM Avg
-0.67
3Y Avg
-1.32
5Y Avg
-1.70
Market Cap
$266.44M
Earnings Per Share (EPS)
-0.69
TTM Avg
-0.60
3Y Avg
-0.18
5Y Avg
-0.21
Market Cap
$267.03M
Earnings Per Share (EPS)
-3.74
TTM Avg
-2.75
3Y Avg
-2.51
5Y Avg
-2.60
Market Cap
$266.50M
Earnings Per Share (EPS)
-0.99
TTM Avg
-0.90
3Y Avg
-0.84
5Y Avg
-0.86
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fate Therapeutics, Inc. (FATE) | $275.66M | -1.05 | -1.40 | -1.83 | -1.95 |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $274.22M | -0.17 | -2.37 | -2.73 | -2.69 |
| Scribe Therapeutics Inc. (SCTX)vs › | $272.42M | N/A | N/A | N/A | N/A |
| SAB Biotherapeutics, Inc. (SABS)vs › | $277.96M | -0.86 | -1.73 | -3.85 | -2.38 |
| Aurora Cannabis Inc. (ACB)vs › | $279.29M | -1.39 | -0.76 | -0.82 | -19.50 |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $282.68M | -1.21 | -0.67 | -1.32 | -1.70 |
| OraSure Technologies, Inc. (OSUR)vs › | $266.44M | -0.69 | -0.60 | -0.18 | -0.21 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $267.03M | -3.74 | -2.75 | -2.51 | -2.60 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $266.50M | -0.99 | -0.90 | -0.84 | -0.86 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $266.05M | -0.48 | -0.82 | -2.37 | -2.68 |
Trailing EPS (TTM)
$-1.05
Forward EPS (Est.)
$-1.07
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.15 |
| 2024-12-31 | -1.64 |
| 2023-12-31 | -1.64 |
| 2022-12-31 | -2.91 |
| 2021-12-31 | -2.24 |
| 2020-12-31 | -2.10 |
| 2019-12-31 | -1.43 |
| 2018-12-31 | -1.19 |
| 2017-12-31 | -1.02 |
| 2016-12-31 | -1.05 |
| 2015-12-31 | -1.18 |
| 2014-12-31 | -1.27 |
| 2013-12-31 | -1.07 |
| 2012-12-31 | -1.61 |
| 2011-12-31 | -1.51 |
